CG
SRPT icon

Caprock Group’s Sarepta Therapeutics SRPT Stock Holding History

Caprock Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,740
Closed -$281K – 400
2018
Q3 		$281K Sell
1,740
-205
-11% -$28K 0.06% 286
2018
Q2 		$257K Buy
+1,945
New +$183K 0.05% 330

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Caprock Group's SRPT Position: Q4 2018 in Review

Caprock Group sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 1,740 shares — an estimated $281K sold.

Caprock Group first reported a position in SRPT in Q2 2018 and held it in 2 quarters. The position peaked at $281K in Q3 2018. 335 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

  • Caprock Group reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Caprock Group sold 1,740 Sarepta Therapeutics shares in Q4 2018, an estimated $281K.
  • Caprock Group first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 2 quarters.
  • Caprock Group's Sarepta Therapeutics position peaked at $281K in Q3 2018.
  • 335 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Caprock Group's 13F filing for Q4 2018, filed 29 Jan 2019.